Search

Your search keyword '"Forman, Stephen J"' showing total 8 results
Start Over Author "Forman, Stephen J" Search Limiters Peer Reviewed Publication Year Range Last 10 years Journal leukemia & lymphoma
8 results on '"Forman, Stephen J"'

3. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study

Author

Rosenzweig, Michael, primary, Palmer, Joycelynne, additional, Tsai, Ni-Chun, additional, Synold, Tim, additional, Wu, Xiwei, additional, Tao, Shu, additional, Hammond, Samantha N., additional, Buettner, Ralf, additional, Duarte, Lupe, additional, Htut, Myo, additional, Karanes, Chatchada, additional, Nathwani, Nitya, additional, Pichiorri, Flavia, additional, Sahebi, Firoozeh, additional, Sanchez, James F., additional, Chowdhury, Arnab, additional, Krishnan, Amrita, additional, Forman, Stephen J., additional, and Rosen, Steven T., additional

Published
2020
Full Text
View/download PDF

5. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Author

Siddiqi, Tanya, primary, Frankel, Paul, additional, Beumer, Jan H., additional, Kiesel, Brian F., additional, Christner, Susan, additional, Ruel, Chris, additional, Song, Joo Y., additional, Chen, Robert, additional, Kelly, Kevin R., additional, Ailawadhi, Sikander, additional, Kaesberg, Paul, additional, Popplewell, Leslie, additional, Puverel, Sandrine, additional, Piekarz, Richard, additional, Forman, Stephen J., additional, and Newman, Edward M., additional

Published
2019
Full Text
View/download PDF

6. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Author

Al-Mansour, Zeina, primary, Li, Hongli, additional, Cook, James R., additional, Constine, Louis S., additional, Couban, Stephen, additional, Stewart, Douglas A., additional, Shea, Thomas C., additional, Porcu, Pierluigi, additional, Winter, Jane N., additional, Kahl, Brad S., additional, Smith, Sonali M., additional, Marcellus, Deborah C., additional, Barton, Kevin P., additional, Mills, Glenn M., additional, LeBlanc, Michael, additional, Rimsza, Lisa M., additional, Forman, Stephen J., additional, Leonard, John P., additional, Fisher, Richard I., additional, Friedberg, Jonathan W., additional, and Stiff, Patrick J., additional

Published
2019
Full Text
View/download PDF

7. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Author

Siddiqi, Tanya, Frankel, Paul, Beumer, Jan H., Kiesel, Brian F., Christner, Susan, Ruel, Chris, Song, Joo Y., Chen, Robert, Kelly, Kevin R., Ailawadhi, Sikander, Kaesberg, Paul, Popplewell, Leslie, Puverel, Sandrine, Piekarz, Richard, Forman, Stephen J., and Newman, Edward M.

Subjects
HISTONE deacetylase inhibitors, KINASE inhibitors, AURORA kinases
Abstract

Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (N = 34; NCT01567709). Patients received alisertib plus vorinostat in 21-day treatment cycles with escalating doses of alisertib following a continuous or an intermittent schedule. All dose-limiting toxicities (DLTs) were hematologic and there were no study-related deaths. The recommended phase 2 dose (RP2D) of the combination was 20 mg bid of alisertib and 200 mg bid of vorinostat on the intermittent schedule. A 13-patient expansion cohort was treated for a total of 18 patients at the RP2D. There were no DLTs at the RP2D, and toxicities were mainly hematologic. Two patients with DLBCL achieved a durable complete response, and two patients with HL achieved partial response. Alisertib plus vorinostat showed encouraging clinical activity with a manageable safety profile in heavily pretreated patients with advanced disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.

Author

Ngo, Dat, Tinajero, Jose, Song, Joo Y., Ma, Huiyan, Quirk, Elizabeth, Koller, Paul, Pourhassan, Hoda, Agrawal, Vaibhav, Stein, Anthony S., Marcucci, Guido, Murphy, Lindsey, Forman, Stephen J., Pullarkat, Vinod, and Aldoss, Ibrahim

Abstract

AbstractReactive pleocytosis in the CSF has been observed with blinatumomab but has not been well-described. We performed a retrospective study of 88 patients who received intrathecal chemotherapy (IT) while on blinatumomab with CSF analyzed to determine if pleocytosis had an impact efficacy and safety. Blinatumomab was used for relapsed/refractory 62.5%, MRD-positive 31.8%, and consolidation in MRD-negative 5.7%. The incidence of pleocytosis in CSF was 51% and was more frequent after day 15 (55.8% vs. 18.2%, p = 0.025). Pleocytosis did not impact CR, clearance of MRD positivity, PFS and OS rates. Lower incidence of non-CNS extramedullary relapse was seen (3.7% vs. 30.8%, p = 0.011) with pleocytosis in CSF. Analysis of CSF by flow cytometry showed median CD4:CD8 ratio of 1.34. In conclusion, CSF pleocytosis is prevalent with blinatumomab but only demonstrated lower rates of non-CNS extramedullary relapse but no impact on CNS relapse or neurotoxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results